Get the Stockscreener App
4.1359
4.82%
-0.2241
Larimar Therapeutics Inc stock is traded at $4.1359, with a volume of 685.87K.
It is down -4.82% in the last 24 hours and up +5.60% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$4.36
Open:
$4.41
24h Volume:
685.87K
Relative Volume:
0.28
Market Cap:
$353.49M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-4.9237
EPS:
-0.84
Net Cash Flow:
$-33.46M
1W Performance:
-13.72%
1M Performance:
+5.60%
6M Performance:
+129.28%
1Y Performance:
-40.63%
1-Day Range:
$4.13
$4.41
1-Week Range:
$4.14
$4.99
52-Week Range:
$1.61
$9.50
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
4.13 | 373.17M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.18 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.85 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.65 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
808.25 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.21 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
Real time breakdown of Larimar Therapeutics Inc. stock performanceQuarterly Profit Report & Risk Managed Investment Strategies - newser.com
Multi factor analysis applied to Larimar Therapeutics Inc.Market Volume Report & Capital Efficient Trade Techniques - newser.com
Is Larimar Therapeutics Inc. stock poised for growth2025 Short Interest & Risk Adjusted Buy and Sell Alerts - newser.com
Larimar Therapeutics (NASDAQ:LRMR) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Intraday pattern recognizer results for Larimar Therapeutics Inc.2025 Buyback Activity & Consistent Profit Focused Trading Strategies - newser.com
How to forecast Larimar Therapeutics Inc. trends using time seriesQuarterly Profit Review & Stock Portfolio Risk Control - newser.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Volatility clustering patterns for Larimar Therapeutics Inc.July 2025 PostEarnings & Free Real-Time Volume Trigger Notifications - newser.com
What MACD and RSI say about Larimar Therapeutics Inc.Trade Ideas & Verified Stock Trade Ideas - newser.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
How Larimar Therapeutics Inc. (ZA71) stock compares with top peersMarket Trend Review & High Conviction Buy Zone Alerts - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.LRMR - PR Newswire
Larimar announces 25 mg, 50 mg data from OL study of nomlabofusp - MSN
Citizens JMP Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
Why Larimar Therapeutics Inc. (ZA71) stock fits value portfoliosDip Buying & Short-Term Trading Alerts - newser.com
Using Python tools to backtest Larimar Therapeutics Inc. strategiesJuly 2025 Pullbacks & Risk Adjusted Buy/Sell Alerts - newser.com
Can you recover from losses in Larimar Therapeutics Inc.2025 Price Momentum & Risk Controlled Stock Alerts - newser.com
Larimar Reports Positive Long-Term Data on Nomlabofusp in Friedreich’s Ataxia - MyChesCo
What’s next for Larimar Therapeutics Inc. stock priceEarnings Overview Report & Accurate Technical Buy Alerts - newser.com
Market reaction to Larimar Therapeutics Inc.’s recent newsWeekly Trend Report & Proven Capital Preservation Tips - newser.com
What analysts say about Larimar Therapeutics Inc stockDouble Top/Bottom Patterns & Low Risk Trading Portfolio - earlytimes.in
Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment? - Yahoo Finance
Why Larimar Therapeutics (LRMR) Is Up After Positive Long-Term Results for Friedreich's Ataxia Therapy - Sahm
Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $21.00 by Analysts at Oppenheimer - Defense World
Why ETFs are accumulating Larimar Therapeutics Inc. (ZA71) stockDividend Hike & Real-Time Stock Movement Alerts - newser.com
Is Larimar Therapeutics Inc. (ZA71) stock worth buying before Fed actionJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Oppenheimer Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Oppenheimer Lowers Larimar Therapeutics (LRMR) Price Target to $21 | LRMR Stock News - GuruFocus
Equities Analysts Issue Forecasts for LRMR FY2027 Earnings - MarketBeat
Is now a turning point for Larimar Therapeutics Inc.2025 Technical Overview & High Accuracy Trade Alerts - newser.com
What analysts say about CTVA stockCandlestick Pattern Analysis & Rapid Capital Appreciation - earlytimes.in
Baird Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $7 - 富途牛牛
Wedbush Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq
Anaphylaxis drives Larimar’s setback, weak efficacy behind MoonLake’s: Clinical Report - BioCentury
Navigating Larimar’s Anaphylaxis Storm: Robust FA Data Presents Risk-Reward Opportunity (NASDAQ:LRMR) - Seeking Alpha
LRMR Analyst Rating Update: Price Target Lowered by Wedbush | LR - GuruFocus
Larimar Therapeutics (NASDAQ:LRMR) Given New $11.00 Price Target at Wedbush - MarketBeat
LRMR: Baird Maintains Rating but Lowers Price Target to $7.00 | - GuruFocus
Wedbush Cuts Price Target on Larimar Therapeutics to $11 From $15, Keeps Outperform Rating - MarketScreener
Baird Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq
Larimar Therapeutics stock price target lowered to $7 at Jones Trading - Investing.com Canada
Larimar Proceeding Toward Accelerated Approval Filing In Friedreich’s Ataxia - insights.citeline.com
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):